MARKET

CTIC

CTIC

CTi Biopharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.9453
-0.0047
-0.49%
Closed 16:00 04/08 EDT
OPEN
0.9315
PREV CLOSE
0.9500
HIGH
0.9500
LOW
0.9305
VOLUME
72.03K
TURNOVER
--
52 WEEK HIGH
1.930
52 WEEK LOW
0.6200
MARKET CAP
69.65M
P/E (TTM)
-1.3694
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CTIC stock price target is 3.750 with a high estimate of 4.000 and a low estimate of 3.500.

EPS

CTIC News

More
  • CTI BioPharma to Present at the Needham Healthcare Conference on Wednesday, Apr. 15
  • PR Newswire · 15h ago
  • How Does Investing In CTI BioPharma Corp. (NASDAQ:CTIC) Impact The Volatility Of Your Portfolio?
  • Simply Wall St. · 03/27 12:00
  • CTI BioPharma reports Q4 results
  • seekingalpha · 03/13 01:29
  • CTI BioPharma Reports Fourth Quarter and Full Year 2019 Financial Results
  • PR Newswire · 03/12 21:05

Industry

Biotechnology & Medical Research
+3.06%
Pharmaceuticals & Medical Research
+2.82%

Hot Stocks

Symbol
Price
%Change

About CTIC

CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL). It is also engaged in evaluating pacritinib for the treatment of adult patients with myelofibrosis. Its earlier stage product candidate, tosedostat, is an oral, once-daily aminopeptidase inhibitor that has demonstrated responses in patients with acute myeloid leukemia (AML). It also evaluates its pipeline candidate paclitaxel poliglumex (Opaxio), which targets solid tumors. It is evaluating Opaxio through cooperative group sponsored trials and investigator-sponsored trials (IST), such as the ongoing maintenance therapy trial in patients with ovarian cancer.
More

Webull offers kinds of CTI BioPharma Corp stock information, including NASDAQ:CTIC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CTIC stock news, and many more online research tools to help you make informed decisions.